Please assess the completion status of the following clinical trial:

Trial Title: Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and 12 years of age and older and weigh at least 40 kg~2. Diagnosed with severe hemophilia A (baseline Factor VIII level less than 1%)~3. History of at least 100 exposure days to any Factor VIII product~Exclusion Criteria:~1. History of Factor VIII inhibitors~2. Kidney or liver dysfunction~3. Diagnosed with another coagulation defect other than hemophilia A

- Gender: MALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Cohort to receive a single low dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single low dose intravenous injection of rFVIIIFc with safety and PK assessments
- B (Type: EXPERIMENTAL): Cohort to receive a single high dose intravenous injection of commercially available rFVIII with safety and PK assessments followed by a single high dose intravenous injection of rFVIIIFc with safety and PK assessments

Based on this trial design, predict the completion outcome and termination type (if applicable).